Fabtech Technologies debuted on October 7, 2026, listing at Rs 192 on NSE (up just 0.52%) and Rs 191 on BSE (at par) to its Rs 191 issue price — before sliding 3.93% to Rs 183.5 in early trade. Market capitalisation stood at Rs 853.46 crore.
The Rs 230.35 crore IPO was a 100% fresh issue of 1.21 crore shares — no offer-for-sale — with proceeds earmarked for working capital, capex and general corporate purposes. It was subscribed only 2.03x (QIB 2.02x, NII 1.97x, RII 2.08x), with the price band set at Rs 181–191 and a minimum retail ticket of Rs 14,325 for a 75-share lot.
The fundamentals looked fine: revenue grew at a 29.8% CAGR (FY23–FY25) to Rs 335 crore and PAT at a 46.2% CAGR to Rs 46.45 crore — a profitable, growing biopharma engineering business. But analysts called the valuation fully priced, and the flat debut agreed. Two mainboard debuts on the same day (Glottis and Fabtech), zero listing pop between them.
Why it matters for founders
Fabtech shows that good financials alone don't guarantee a listing pop — pricing does. The IPO window is open, but only for defensibly priced issues. If you're planning a public debut, benchmark against the two October 7 listings: strong numbers at a full price gets you par; a discount to fair value is what buys the pop that builds momentum.